Maryann J. Kwa, MD

Articles by Maryann J. Kwa, MD

Dr. Kwa on the TAILORx Trial in Breast Cancer

July 5th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

ByMaryann J. Kwa, MD

June 27th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

Latest Updated Articles

Dr. Kwa on the Potential Impact of Biosimilars in Oncology
Published: June 27th 2018 | Updated:
Dr. Kwa on the TAILORx Trial in Breast Cancer
Published: July 5th 2018 | Updated:

Maryann J. Kwa, MD

Articles by Maryann J. Kwa, MD

Dr. Kwa on the TAILORx Trial in Breast Cancer

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma